Ergomed plc Anne Whitaker appointed to the Board as NED
RNS Number : 3983O
10 June 2022
Anne Whitaker appointed to the Board as Non-Executive
Guildford, UK - 10 June 2022: Ergomed plc (LSE: ERGO) ("Ergomed"
or the "Company"), a company focused on providing specialised
services to the pharmaceutical industry, today announces that Anne
Whitaker will join the Board as an independent Non-Executive
Director following the Company's AGM later today, 10 June 2022.
Anne Whitaker has extensive life sciences industry experience,
having worked across the pharmaceutical, biotech and specialty
pharma sectors for the last thirty years in the US and
internationally. Anne previously held a number of senior executive
roles at Sanofi, GlaxoSmithKline, Bausch Health Company and Synta
Pharmaceuticals, and most recently, she held the position of Chief
Executive Officer, and subsequently Chairperson of Aerami
Therapeutics, a private life science company. She has served as a
Non-Executive Director at a number of UK-listed healthcare /
pharmaceutical services companies including UDG Healthcare and
Vectura Group and is currently on the board of a number of global
Anne is recognised as a biopharma industry influencer, advisor
and leader, having received numerous awards from PharmaVoice,
WomenInc and Fierce Pharma. She holds a BSc in Chemistry and
Business from the University of North Alabama.
Dr. Miroslav Reljanović, Executive Chairman of Ergomed,
commented: "Anne has an excellent track record and extensive global
pharmaceutical industry experience and we are delighted to have her
joining the Board. I believe that her global network and deep
understanding of the pharmaceutical services industry will support
the continued growth and strategic development of Ergomed's CRO and
PV businesses internationally."
Anne Whitaker, incoming Non-Executive Director, said: "I have
witnessed Ergomed's consistent growth in recent years and I am
highly excited to be joining a leading provider of specialised
services to the pharmaceutical industry. I look forward to working
with the Board to continue Ergomed's growth trajectory as we
support customers and patients around the world."
The following information regarding the appointment of Anne
Michelle Clem Whitaker, aged 55, is disclosed under Schedule 2(g)
of the AIM Rules for Companies:
Current directorships and/or Former directorships and/or partnerships
partnerships: (within the last five years):
Aerami Therapeutics Holdings, Chason Dreams, LLC
Anne Whitaker Group, LLC Cree, Inc.
Bryn Pharma LLC ECR Pharmaceuticals Co., Inc.
Caladrius Biosciences, Inc. KNOW Bio, LLC
Curio Digital Therapeutics, Inc. UDG Healthcare, Plc
Faron Pharmaceuticals Oy Vast Therapeutics Inc.
Mallinckrodt Plc* Vectura Group Limited
Nykode Therapeutics ASA Wolfspeed, Inc.
OraSure Technologies Inc.
Trinity Life Sciences
Ms Whitaker does not have any beneficial interest in the
ordinary shares of the Company.
*Mallinckrodt plc filed for bankruptcy in October 2020 while
facing class action litigation.
Save as set out above, no further information regarding Anne
Whitaker is required to be disclosed pursuant to Schedule Two,
paragraph (g) of the AIM Rules for Companies.
Ergomed plc Tel: +44 (0) 1483 402
Miroslav Reljanović (Executive
Richard Barfield (Chief Financial Officer)
Keith Byrne (Senior Vice-President,
Capital Markets & Strategy)
Numis (Nominated Adviser and Joint Tel: +44 (0) 20 7260
Freddie Barnfield / Euan Brown (Nominated
James Black (Broker)
Peel Hunt LLP (Joint Broker) Tel: +44 (0) 20 7418
James Steel / Dr Christopher Golden 8900
Consilium Strategic Communications Tel: +44 (0) 20 3709
- for UK enquiries 5700
Chris Gardner / Matthew Neal / Angela email@example.com
About Ergomed plc
Ergomed provides specialist services to the pharmaceutical
industry spanning all phases of clinical development, post-approval
pharmacovigilance and medical information. Ergomed's fast-growing
services business includes an industry-leading suite of specialist
pharmacovigilance (PV) solutions, integrated under the
PrimeVigilance brand, a full range of high-quality clinical
research and trial management services under the Ergomed brand
(CRO) and mission-critical regulatory compliance and consulting
services under the ADAMAS brand. For further information, visit:
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact firstname.lastname@example.org or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
(END) Dow Jones Newswires
June 10, 2022 02:01 ET (06:01 GMT)
Gráfica de Acción Histórica
De Jul 2022 a Ago 2022
Gráfica de Acción Histórica
De Ago 2021 a Ago 2022